Selective Beta-Blockers on Chronic Obstructive Pulmonary Disease: A Literature Review
DOI:
https://doi.org/10.36497/respirsci.v4i3.131Keywords:
beta-blockers, COPD, COPD exacerbation, mortality, quality of lifeAbstract
Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) are usually coexisting. While beta-blockers are the indispensable management of an array of cardiovascular diseases, inhaled beta-receptor agonists are the central treatment for COPD patients. This review aims to assess the effect of beta-blockers on exacerbation rate, mortality, and quality of life among the COPD population. After the search on Cochrane Library, Pubmed, and Scopus, 15 relevant full-text articles published between 2012 and 2022 were included. We compared selective beta-blockers versus either non-users or non-selective agents. The results showed that selective beta-blockers did not increase the mortality and exacerbation rate in the COPD population and evidence on health-related quality of life is still sparse. However, more RCTs should be carried out for more precise information.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Respiratory Science
![Creative Commons License](http://i.creativecommons.org/l/by-nc/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.